European heart journal open最新文献

{"title":"Addiction as a cardiometabolic disease: a neurocardiometabolic framework and the emerging role of GLP-1 receptor therapies.","authors":"Jose Seijas-Amigo, Ángel Salgado-Barreira, Sonia Eiras, Susana Arias-Rivas, Gemma Rodriguez-Carnero, Moisés Rodriguez-Mañero, Jose Ramon Gonzalez-Juanatey","doi":"10.1093/ehjopen/oeag101","DOIUrl":"10.1093/ehjopen/oeag101","url":null,"abstract":"<p><p>Substance-use disorders are major accelerators of cardiometabolic disease, yet this dimension remains insufficiently recognized within addiction care. Individuals with substance-use disorders frequently exhibit hypertension, adverse lipid profiles, visceral adiposity, metabolic syndrome, chronic low-grade inflammation and autonomic imbalance, contributing to markedly elevated cardiovascular morbidity and premature mortality. The recent European Society of Cardiology Clinical Consensus Statement on mental health and cardiovascular disease highlights this gap and calls for structured cardiometabolic assessment and prevention strategies within behavioural and psychiatric population. Glucagon-like peptide-1 receptor therapies have emerged as multisystem agents relevant to both addictive behaviour and cardiometabolic health. Experimental and early clinical evidence demonstrates reductions in craving, improved reward regulation and attenuation of impulsive consumption across alcohol, nicotine, stimulant use and binge-type eating, mediated through gut-brain communication, mesolimbic dopamine circuitry, hypothalamic pathways and stress-responsive networks. In parallel, these therapies induce clinically meaningful reductions in body weight, visceral adiposity, blood pressure and inflammatory burden, while improving glucose regulation and cardiometabolic markers. Large cardiovascular outcome trials demonstrate reductions in major adverse cardiovascular events in high-risk populations, and emerging primary-prevention analyses report favourable changes in estimated cardiovascular risk even without established cardiovascular disease. This review integrates biological, clinical and real-world evidence to propose a unified neurocardiometabolic framework in which glucagon-like peptide-1 receptor therapies may simultaneously influence addictive behaviour and long-term cardiovascular risk trajectories. We outline mechanistic foundations and potential clinical applications within detoxification programmes, relapse-prevention settings, dual-diagnosis services and addiction care, while highlighting the need for further clinical validation before routine implementation.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag101"},"PeriodicalIF":4.3,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13329405/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional abnormalities of cardiac sympathetic innervation in athletes with nonischaemic left ventricular scar and exercise-related ventricular arrhythmias.","authors":"Alessandro Zorzi, Francesca Graziano, Domenico Corrado, Pietro Zucchetta, Diego Cecchin","doi":"10.1093/ehjopen/oeag114","DOIUrl":"10.1093/ehjopen/oeag114","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag114"},"PeriodicalIF":4.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13361980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148440472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The hidden IVUS effect: a meta-epidemiological analysis of control-arm optimization and treatment-effect attenuation in contemporary IVUS-guided PCI trials.","authors":"Giuseppe Panuccio, Youssef S Abdelwahed, Ulf Landmesser, Salvatore De Rosa, Daniele Torella","doi":"10.1093/ehjopen/oeag111","DOIUrl":"10.1093/ehjopen/oeag111","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag111"},"PeriodicalIF":4.3,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13344427/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148414096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of pacing-induced cardiomyopathy in patients undergoing AV nodal ablation: insights from a Delphi process and retrospective cohort study.","authors":"Nikola Kozhuharov, Anna Maria Gstoehl, Peter Calvert, Ioanna Koniari, Ali Najm, Mark T Mills, Kaung Thu, Panagiotis Xydis, Raphael Usteri, Agnieszka Babinska, Andreas Haeberlin, Tobias Reichlin, Christian Sticherling, Haran Burri, David Justin Wright, Archana Rao, Dhiraj Gupta","doi":"10.1093/ehjopen/oeag102","DOIUrl":"10.1093/ehjopen/oeag102","url":null,"abstract":"<p><strong>Aims: </strong>Pacing-induced cardiomyopathy (PICM) is a recognized complication of pace-and-ablate therapy. Early identification of patients at risk may allow tailored strategies, including upfront biventricular or conduction system pacing.</p><p><strong>Purpose: </strong>This study aimed to identify predictors of PICM in patients undergoing pace-and-ablate therapy, combining expert consensus with clinical validation.</p><p><strong>Methods and results: </strong>A three-round Delphi process involving 12 electrophysiologists prioritized candidate predictors of PICM. Consecutive patients undergoing atrioventricular node ablation with non-cardiac resynchronization therapy (CRT) devices at Liverpool Heart and Chest Hospital (2015-2019) were retrospectively analysed. The primary endpoint was PICM, defined as ≥10% reduction in left ventricular ejection fraction (LVEF) to <50%, adjudicated by two independent cardiologists. Cox regression was used to identify independent predictors. The Delphi process prioritized baseline LVEF, intrinsic and paced QRS duration, RV lead position, and key comorbidities. Among 658 ablation patients, 323 (median age 76 years, 67% female) had non-CRT devices. Over a median follow-up of 192 days (IQR, 63-1003 days), 33 patients (9.8%) developed PICM. In multivariable analysis, RV free wall vs. septal lead position [hazard ratio (HR) 4.896, 95% confidence interval (CI) 1.263-18.973, <i>P</i> = 0.022], intrinsic QRS duration (HR 1.247 per 10 ms, 95% CI 1.064-1.462, <i>P</i> = 0.006), independently predicted PICM. Exploratory analyses suggested that higher intrinsic QRS duration was associated with increased PICM risk; however, these findings were based on a small number of events and should be interpreted with caution.</p><p><strong>Conclusion: </strong>Intrinsic QRS duration and free wall RV lead position independently predict PICM in pace-and-ablate patients. These findings support early risk stratification and may guide personalized pacing strategies.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 3","pages":"oeag102"},"PeriodicalIF":4.3,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148355145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-related differences in histopathology and hormonal associations in ascending aortic aneurysms.","authors":"Tamara C Borsboom, Maximiliaan L Notenboom, Lambertus J Wisse, Kevin M Veen, Jonathan R G Etnel, Jolien W Roos-Hesselink, Johanna J M Takkenberg, Marie José T H Goumans, Marco C DeRuiter","doi":"10.1093/ehjopen/oeag084","DOIUrl":"10.1093/ehjopen/oeag084","url":null,"abstract":"<p><strong>Aims: </strong>Sex-related differences in ascending aorta aneurysm (AscAA) pathology and the underlying mechanisms remain incompletely understood. In this study, sex-specific patterns of aortic media degeneration (MD) in idiopathic AscAA were investigated.</p><p><strong>Methods and results: </strong>Aortic tissue and blood samples were obtained from 32 patients undergoing elective AscAA resection (mean age 65.6 years, 25% women). Two donor aortas served as healthy controls. Tissues were evaluated using a modified consensus scoring system assessing elastin integrity, mucoid extracellular matrix accumulation (MEMA), smooth muscle cell organization, and collagen remodelling. Immunohistochemistry was used to quantify extracellular matrix and remodelling markers. Outcome parameters included aortic diameter, immunohistochemical profiling, MD scores, and sex hormone profiling. Absolute ascending aortic diameters did not differ between sexes. Women exhibited significantly more advanced and diffuse MD across all sampled locations, with higher total MD scores before and after adjustment for aortic size. This was attributed to increased elastin degradation, MEMA, and elevated local MMP2 expression, consistent with a degradative remodelling profile. In contrast, men displayed a more focal and inflammatory phenotype, characterized by increased MMP9, cKIT, and CD68 expression, and relatively thicker media. Circulating hormone levels were reduced in both sexes but were not directly associated with MD severity. However, female-specific decreases in DHEA and male-specific decreases in testosterone, AMH, and androstenedione were observed.</p><p><strong>Conclusion: </strong>This study reveals pronounced sex-specific differences in AscAA wall degeneration. Women demonstrate a structurally more vulnerable aortic wall at comparable dilatation, fuelling discussion for revision of female treatment plans.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag084"},"PeriodicalIF":4.3,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13373786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148474885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide-1 receptor agonists are associated with cardiac, cancer- and mortality-related benefits in diabetic patients treated with anthracyclines.","authors":"Sunnia T Chen, Teodora Donisan, Bradley R Lewis, Vidur Kailash, Sandra Herrmann, Kathryn J Ruddy, David Yat-Chung Cheung, Danielle Desautels, Davinder S Jassal, Joerg Herrmann","doi":"10.1093/ehjopen/oeag109","DOIUrl":"10.1093/ehjopen/oeag109","url":null,"abstract":"<p><strong>Aims: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce major adverse cardiovascular events in diabetics. This study aimed to investigate the cardiac, cancer, and overall mortality effects of GLP-1 RAs in diabetics treated with anthracyclines.</p><p><strong>Methods and results: </strong>We retrospectively identified 1384 diabetics treated with anthracyclines from 2013 to 2023; 56 received GLP-1 RAs between their first and last dose of anthracycline. These patients were propensity score matched 4:1 to 224 controls without concurrent GLP-1 RA use. Because stage was not available for 10 of the 56 patients, a repeat analysis was conducted with additional matching for cancer stage in 46 cases and 92 controls. Major endpoints were rate of all-cause and cancer-related and cardiovascular disease (CVD)-related mortality, no evidence of disease (NED), and hospitalization for CVD including heart failure (HF), over 5 years. Survival analyses were conducted using cause-specific hazards Cox regression. Patients on GLP-1 RAs had a significantly lower 5 year overall mortality (HR 0.46, CI 0.24-0.87, <i>P</i> = 0.007) and cancer-related mortality (HR 0.42, CI 0.19-0.91, <i>P</i> = 0.03). This mortality risk reduction remained significant even when accounting for covariates (HR 0.39, CI 0.20-0.75, <i>P</i> = 0.002). The percentage of patients with NED was higher in the GLP-1 RA than control group (60.9% vs. 38.0%, <i>P</i> = 0.007). A decline in left ventricular ejection fraction was seen in controls but not in patients on GLP-1 RAs. There was no significant difference in CVD hospitalization; the rate of HF-related hospitalization was very low overall.</p><p><strong>Conclusion: </strong>GLP-1 RAs may offer survival benefits and better cancer- and cardiac function-related outcomes in diabetics undergoing anthracycline chemotherapy.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag109"},"PeriodicalIF":4.3,"publicationDate":"2026-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13384431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148611236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proresolving mediators as cardiovascular biomarkers: solo players or an orchestra?","authors":"Luís M Cardoso Dos Santos, Magnus Bäck","doi":"10.1093/ehjopen/oeag110","DOIUrl":"10.1093/ehjopen/oeag110","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag110"},"PeriodicalIF":4.3,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific associations of perioperative Resolvin D1 and D2 dynamics with postoperative atrial fibrillation in cardiac surgery: a secondary analysis of a prospective observational study.","authors":"Melina Heine, Felix Ulbrich, Samuel Justice, Babak Saravi, Simon A Amacher, Julian Hubrich, Leonard Simeth, Asishana Osho, Charles N Serhan, Jochen D Muehlschlegel, Jakob Wollborn","doi":"10.1093/ehjopen/oeag095","DOIUrl":"10.1093/ehjopen/oeag095","url":null,"abstract":"<p><strong>Aims: </strong>Postoperative atrial fibrillation (POAF) is a prevalent and clinically significant complication that occurs after cardiac surgery. While inflammation has been linked to its onset, the role of active inflammatory resolution-mediated by a group of mediators named specialized pro-resolving mediators (SPMs)-remains unclear. Since SPMs, such as resolvins, actively terminate inflammation and restore tissue homeostasis, impaired resolution could contribute to persistent postoperative inflammation and the development of POAF.</p><p><strong>Methods: </strong>This study is a secondary analysis of a single-centre prospective cohort of 319 adult patients who underwent cardiac surgery. The occurrence of POAF was identified. Resolvin D1 (RvD1) and D2 (RvD2) levels were measured during the perioperative period. The association between resolvin levels and POAF was assessed using a mixed-effects Tobit regression model. The interaction between gender, POAF, and resolvin levels was furthermore investigated.</p><p><strong>Results: </strong>Patients who developed POAF exhibited significantly higher predicted perioperative levels of RvD1 [mean ratio (MR-interpreted analogously to an odds ratio): 1.19, <i>P</i> < 0.001] and significantly lower predicted levels of RvD2 (MR: 0.80, <i>P</i> < 0.001) compared to those without POAF. The association between POAF and RvD1 was amplified in women compared to men (<i>P</i> = 0.012). A similar pattern was noted for RvD2, with women tending to show a more pronounced decrease in RvD2 levels associated with POAF. However, this finding did not reach statistical significance (<i>P</i> = 0.054).</p><p><strong>Conclusion: </strong>POAF is associated with elevated RvD1 and reduced RvD2 levels, suggesting a differential response and potentially distinct roles of the two pro-resolving mediators in patients with POAF. Additionally, these associations differ by sex, indicating that inflammatory resolution mechanisms may vary between males and females.</p><p><strong>Registration: </strong>German Clinical Trials Registry (DRKS No. 00017057), Date of registration 5 April 2019, www.drks.de.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag095"},"PeriodicalIF":4.3,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview of methodology and characteristics of national acute coronary syndrome registries in high-income countries: a scoping review.","authors":"Justine Chan, Natalie Ward, Judith Finn, Adil Rajwani, Jing Pang, Mikhail Alexander, Khang Duong Nguyen, Jyoti Sharma, Carl Schultz, Gerald F Watts, Markus P Schlaich, Christopher M Reid, Graham S Hillis","doi":"10.1093/ehjopen/oeag100","DOIUrl":"10.1093/ehjopen/oeag100","url":null,"abstract":"<p><strong>Aims: </strong>The role of clinical quality registries is to collect structured observational data in routine clinical practice to monitor the quality of care provided to specific patient populations. There is currently no standardized methodology of how to establish registry platforms. The objective of this scoping review is to provide an overview of the methodology and characteristics of established national acute coronary syndrome registries.</p><p><strong>Methods and results: </strong>Three electronic databases were searched to identify national registries in high-income countries collecting routine clinical data on adult patients with suspected and/or diagnosed acute coronary syndrome. Articles published from the year 2000 onwards that described the protocol and/or quantitative results of such registries located in 25 countries with the largest gross domestic product were included. There were 24 countries with an established national registry, of which nine are currently active. Inclusion criteria varied across these registries, with a predominant focus on either a suspected or confirmed diagnosis of acute coronary syndrome or myocardial infarction. The primary clinical outcomes measured were all-cause mortality and major adverse cardiovascular events during hospitalization, as well as at 30-day and/or 1 year time points. The main sources of follow-up data were hospital discharge records and administrative data.</p><p><strong>Conclusion: </strong>Globally, acute coronary syndrome clinical quality registries share similar fundamental objectives of monitoring and improving or sustaining the highest quality of care. However, there is considerable variation in the design of national registries and better harmonization of fundamental issues, such as who is included, core data, and key outcomes, would be beneficial.</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 4","pages":"oeag100"},"PeriodicalIF":4.3,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13322397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' response: septal reduction therapy for obstructive hypertrophic cardiomyopathy.","authors":"Andreas Schelldorfer, Alexander Kutz, H Yakup Yakupoglu","doi":"10.1093/ehjopen/oeag088","DOIUrl":"10.1093/ehjopen/oeag088","url":null,"abstract":"","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":"6 3","pages":"oeag088"},"PeriodicalIF":4.3,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13273420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}